A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop differentiated, potential best-in-class medicines that could lead to improved patient outcomes, reduced side effects, improved quality of life, and expanded market access. Our pipeline targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 314K | - | - |
| Net Income | -343M | -343M | -270M | - | -130M | -79M |
| EPS | $-221.65 | $-221.65 | $-204.82 | $-260.70 | $-4.05 | $-6.66 |
| Free Cash Flow | -277M | -277M | -233M | -185M | -95M | -55M |
| ROIC | -52.8% | -45.3% | -40.2% | - | -32.5% | -42.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.05 | 0.05 | 0.00 | 0.05 | 0.01 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -363M | -363M | -299M | -254M | -134M | -80M |
| Operating Margin | 0.0% | - | - | -81035.0% | - | - |
| ROE | -47.4% | -49.2% | -40.2% | - | -32.9% | -42.3% |
| Shares Outstanding | 102M | 102M | 102M | 81M | 32M | 43M |
Viridian Therapeutics, Inc.\DE passes 0 of 9 quality checks, indicating weak fundamentals.
Viridian Therapeutics, Inc.\DE (VRDN) has a 5-year average return on invested capital (ROIC) of -40.1%. This is below average and may indicate limited pricing power.
Viridian Therapeutics, Inc.\DE (VRDN) has a market capitalization of $1.6B. It is classified as a small-cap stock.
Viridian Therapeutics, Inc.\DE (VRDN) does not currently pay a regular dividend.
Viridian Therapeutics, Inc.\DE (VRDN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Viridian Therapeutics, Inc.\DE (VRDN) generated $-277 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Viridian Therapeutics, Inc.\DE (VRDN) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Viridian Therapeutics, Inc.\DE (VRDN) reported earnings per share (EPS) of $-221.65 in its most recent fiscal year.
Viridian Therapeutics, Inc.\DE (VRDN) has a return on equity (ROE) of -49.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for Viridian Therapeutics, Inc.\DE (VRDN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Viridian Therapeutics, Inc.\DE (VRDN) has a book value per share of $7.07, based on its most recent annual SEC filing.
No recent press releases.